Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2025 | PERSIAN: early results of SBRT with apalutamide and ADT in mHSPC

Giulio Francolini • 14 Feb 2025

GU Cancers 2025

PERSIAN

Giulio Francolini, MD, University of Florence, Florence, Italy, discusses early findings from the Phase II PERSIAN trial (NCT05717660) of stereotactic body radiotherapy (SBRT) with apalutamide and androgen deprivation therapy (ADT) in patients with low-burden metastatic hormone-sensitive prostate cancer (mHSPC). While overall rates of early biochemical response were similar between treatment arms, patients with fewer than three metastatic sites experienced a greater benefit from SBRT. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.